Malignant Pleural Mesothelioma, Advanced Clinical Trial
Official title:
Observation of the Efficacy and Safety of Oncolytic Adenovirus Injection Combined With Programmed Death Receptor Inhibitors in Treatment of Advanced Malignant Pleural Mesothelioma : a Single Center, Prospective, Case Registration Study
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
By monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (PD-1) inhibitors, we analyze and explore the effectiveness and safety of using oncolytic virus drugs. Exploring the influencing factors of using oncolytic adenovirus injection combined with PD-1 inhibitors to reverse immune resistance in MPM patients. Evaluate the safety of the drug, and finally evaluate the quality of life of patients using oncolytic adenovirus injection(H101) combined with PD-1 inhibitors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03213301 -
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
|
Phase 2 | |
| Withdrawn |
NCT03786419 -
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
|
Phase 2 |